Photo Biomodulation Therapy for Alveolar Osteitis Recovery in Oral Contraceptive Users

NCT06865508 | Completed DMC

• 1 other identifier: BUC-IACUC-231015-38
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

does laser effect on alveolar osteitis recovery in oral contraceptive users ?

Conditions

Alveolar Osteitis

Keywords

alveolar osteitis and oral contraceptive

Outcome Measures

Primary Outcomes (2)

• pain intensity by VAS

  Pain intensity measured using a Visual Analog Scale (VAS) at day0, day7, day14 post-treatment.

  4 weeks

• Socket volume .

  measured using \[specific measurement technique, volumetric analysis\] at day0, day14 and 1-month post-treatment

  4 weeks

Secondary Outcomes (1)

• Quality of life assessed

  4 weeks

Study Arms (2)

1. Experimental Group: Laser therapy combined with zinc oxide eugenol dressing.

EXPERIMENTAL

* Laser therapy was administered using a low-level laser device with the following parameters: \[ wavelength 980 nm810, power 500mw, and duration 90 seconds (30second for each 3 sides\]. * Zinc oxide eugenol dressing was applied immediately before the laser therapy. * The intervention will be performed at \[specified intervals every day 0, day7, day 14, day 30)\]

Device: Laser therapy; Device: zinc oxide eugenol dressing.

control group

ACTIVE COMPARATOR

zinc oxide eugenol dressing.

Device: zinc oxide eugenol dressing.

Interventions

Laser therapy DEVICE

Laser therapy was administered using a low-level laser device with the following parameters: \[ wavelength 980 nm810, power 500mw, and duration 90 seconds (30second for each 3 sides\].

1. Experimental Group: Laser therapy combined with zinc oxide eugenol dressing.

zinc oxide eugenol dressing. DEVICE

zinc oxide eugenol dressing.

1. Experimental Group: Laser therapy combined with zinc oxide eugenol dressing.; control group

Eligibility Criteria

• Age: 25 Years - 40 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Female patients aged 25-40 years. Currently using oral contraceptives for at least 3 months prior to participation.
• Diagnosed with dry socket (alveolar osteitis) based on clinical criteria.

You may not qualify if:

• Presence of systemic diseases (e.g., diabetes, immunodeficiency disorders). Smoking or tobacco use. Allergies to zinc oxide or other study materials. Use of antibiotics or anti-inflammatory medications within the last 2 weeks. Pregnancy or breastfeeding.

Sponsors & Collaborators

• Badr University: lead

Study Sites (1)

physical therapy at Badr University in Cairo(BUC)

Cairo, 11829, Egypt

Location

MeSH Terms

Conditions

Dry Socket

Interventions

Laser Therapy

Condition Hierarchy (Ancestors)

Mouth Diseases; Stomatognathic Diseases

Intervention Hierarchy (Ancestors)

Therapeutics; Ablation Techniques; Surgical Procedures, Operative

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: double
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer

Model Details: This study is a randomized clinical trial (RCT) designed to evaluate the effectiveness of laser therapy combined with zinc oxide eugenol dressing in comparison to zinc oxide eugenol dressing alone in the management of dry socket among females using oral contraceptives. The study assessed outcomes related to pain, quality of life, and socket volume.

Study Record Dates

• First Submitted: March 4, 2025
• First Posted: March 10, 2025
• Study Start: November 1, 2023
• Primary Completion: November 1, 2024
• Study Completion: December 30, 2024
• Last Updated: March 10, 2025

Record last verified: 2025-03

Locations

EG (1)